Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study

This study has been completed.
Ortho-McNeil Janssen Scientific Affairs, LLC
Information provided by (Responsible Party):
Donna Londino, Georgia Regents University Identifier:
First received: July 12, 2006
Last updated: January 13, 2015
Last verified: January 2015

This study will be an open-label, 12-week trial of risperidone in subjects with Asperger's Disorder, according to Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) Criteria. The study has two arms, one involving pre- and post-treatment MRS studies, and one without MRS. The MRS arm will study 18-20 subjects ages 6 and above, with a target of 14 completing patients. For both arms, we plan to a enroll at total of 30 patients to achieve completion for 24 patients. The non-MRS arm of the study will include subjects 6-18 years of age, the bulk of which have completed the study as of the writing of this updated revision. Our hypotheses are that treatment of Asperger's patients with a low dose of risperidone will:

  1. decrease ratios of N-acetylaspartate (NAA), creatine, phosphocreatine (Cr + PCr), and choline in the prefrontal lobe, and
  2. decrease the severity of negative symptoms and overall improve social behavior, and
  3. that the two will be correlated.

Specific Aims

The primary objectives of this trial are to:

  • Further assess and investigate the utility of risperidone in the treatment Asperger's disorder.
  • Assess the efficacy of risperidone in normalizing increased frontal lobe metabolites.
  • Assess the efficacy of risperidone in normalizing symptoms in Asperger's disorder patients using standardized rating scales to assess the impact on negative symptoms and on social interaction.
  • Determine whether risperidone's effect on clinical improvement of Asperger's disorder, i.e., negative symptoms, is correlated with normalization of frontal lobe metabolites
  • Accrue safety and tolerability data on risperidone for this population of patients.

This information could potentially be used to provide pilot data for a double blind trial

Condition Intervention Phase
Asperger's Disorder
Drug: Risperidone
Other: Magnetic Resonance Spectroscopy
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Biological Basis of Therapy for Negative Symptom Spectrum Disorders: Risperdal Effect on Frontal Metabolism in Asperger's Disorder

Resource links provided by NLM:

Further study details as provided by Augusta University:

Primary Outcome Measures:
  • Chang in the Scale for the Assessment of Negative Symptoms (SANS) [ Time Frame: Baseline, Week 3, 6, 9, 12 and up to 7 weeks post treatment ]

Secondary Outcome Measures:
  • Change in Positive and Negative Symptom Scale (PANNS) [ Time Frame: Baseline, Week 3, 6, 9, 12 and up to 7 weeks post treatment ]
  • Change in Brief Psychiatric Rating Scale (BPRS) [ Time Frame: Baseline, Week 3, 6, 9, 12 and up to 7 weeks post treatment ]
  • Change in Montgomery Asberg Rating Scale (MADRS) [ Time Frame: Baseline, Week 3, 6, 9, 12 and up to 7 weeks post treatment ]
  • Change in Global Assessment Scale (GAS) [ Time Frame: Baseline, Week 3, 6, 9, 12 and up to 7 weeks post treatment ]
  • Change in Abnormal Involuntary Movement Scale (AIMS) [ Time Frame: Baseline, Week 3, 6, 9, 12 and up to 7 weeks post treatment ]
  • Change in Neurocognitive test battery [ Time Frame: Baseline, 12 weeks ]

Enrollment: 23
Study Start Date: November 2001
Study Completion Date: May 2007
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Magnetic Resonance Spectroscopy
Subjects will receive a baseline MRS prior to and within 7 day of completing 12 weeks of standard treatment with.
Drug: Risperidone
12 weeks of treatment with risperidone 0.25 to 11 mg per day.
Other Name: Risperdal
Other: Magnetic Resonance Spectroscopy
Subjects will receive a standard MRS to assess the concentrations and ratios of brain metabolites N-acetylaspartate, creatine, phosphocreatine, and choline.
Other Name: MRS
Subjects will receive 12 weeks of standard treatment of risperidone 0.25 to 11 mg per day, or early termination. Dose titration will based on response and tolerability.
Drug: Risperidone
12 weeks of treatment with risperidone 0.25 to 11 mg per day.
Other Name: Risperdal

  Show Detailed Description


Ages Eligible for Study:   6 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must be age 6 -18 for the Non-MRS arm of the study, and age 6 or above for the MRS arm of the study.
  2. If applicable, a parent or legal guardian or legal representatives of study subject must provide informed consent and sign an informed consent document.
  3. Female patients of childbearing age must be either postmenopausal for at least one year, surgically incapable of childbearing, or effectively practicing an acceptable method of contraception (oral or parenteral hormonal contraceptives, intrauterine device; barrier and spermicide. Abstinence is not an acceptable method).
  4. Female patients of child-bearing potential must have a negative pregnancy test to be performed at screening and baseline.
  5. Patients must meet DSM-IV criteria for Asperger's Disorder. Other Axis I & II disorders excluded are listed below.
  6. Patient must not have other serious, unstable illnesses and must be otherwise physically healthy on the basis of a physical examination, medical history, electrocardiogram and the results of blood biochemistry, hematology tests and a urinalysis.
  7. Patient must have a negative urine drug screen with the exception of amphetamines if the patient is being treated with stimulants for four months or longer prior to entry.

Exclusion Criteria:

  1. Patients who meet DSM-IV criteria for any psychotic disorder including schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder,psychotic disorder not otherwise specified, major depression with psychotic features, or bipolar disorder.
  2. Patients who meet DSM-IV criteria for schizoid, schizotypal, or paranoid personality disorder. Patients who meet DSM-IV criteria for autistic disorder or pervasive developmental disorder.
  3. Claustrophobic patients and those otherwise unable to successfully complete the MRS procedure prior to baseline.
  4. Patients who meet criteria for substance abuse or dependence within the past three months. (Nicotine and caffeine are exceptions).
  5. Patients believed by the investigator to be at significant risk for suicidal or violent behavior during the course of the trial.
  6. Female patients who are pregnant or nursing.
  7. Patients with a known or suspected seizure disorder.
  8. If the results of the serum alanine transaminase (ALT) or aspartate aminotransferase (AST) are more than twice the upper limit of the central laboratory's reference range, the patient may not be enrolled. If the results of any other biochemistry, hematology or urinalysis tests are not within the central laboratory's reference ranges, the patient can be enrolled only on condition that the investigator judges that the deviations are not clinically significant. This should be clearly recorded on the laboratory report and in the source documents.
  9. Patients with a history of neuroleptic malignant syndrome (NMS) or similar encephalopathic syndrome.
  10. Patients who, by history, have received treatment with Risperdal or another neuroleptic (including olanzapine or quetiapine) within three months of baseline evaluation. Patients who have received a depot antipsychotic within one treatment cycle prior to screening. Patients who have taken an antidepressant, or lithium within 4 weeks of the trial, 6 weeks for fluoxetine. Patients who have taken any psychotropic medication within 1 week of the trial. Patients who require concomitant medications during the trial.
  11. Patients with a suspected history of hypersensitivity or intolerance to risperidone.
  12. Patients with a known or suspected history of severe drug allergy or hypersensitivity (e.g., Steven Johnson's syndrome)
  13. Patients with an anticipated life expectancy of six months or less.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00352196

United States, Georgia
Medical College of Georgia, Dept. of Psychiatry
Augusta, Georgia, United States, 30912-3800
Sponsors and Collaborators
Augusta University
Ortho-McNeil Janssen Scientific Affairs, LLC
Principal Investigator: Jeffrey L Rausch, MD Augusta University
Study Director: Donna L Londino, MD Augusta University
  More Information

Responsible Party: Donna Londino, Associate Professor, Georgia Regents University Identifier: NCT00352196     History of Changes
Other Study ID Numbers: RIS-EMR-4026
MCG HAC File #01-09-063 ( Other Identifier: Institutional Review Board )
Study First Received: July 12, 2006
Last Updated: January 13, 2015

Keywords provided by Augusta University:
Asperger's Disorder
Magnetic Resonance Spectroscopy
Social Skills

Additional relevant MeSH terms:
Asperger Syndrome
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents processed this record on May 25, 2017